News and Media
News and Media
Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures
July 29, 2022
Onxeo announces a Combined General Meeting on August 17, 2022
July 12, 2022
Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
June 30, 2022
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
June 16, 2022
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
April 7, 2022
Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million
April 6, 2022
Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022
March 31, 2022
Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors
March 9, 2022
Onxeo Announces its Financial Agenda for 2022
January 13, 2022
Onxeo appoints Julien Miara as new interim CEO
January 3, 2022
Onxeo Continues to Strengthen its Board of Directors
November 23, 2021
New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments
August 12, 2021
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
December 10, 2020
Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020
December 10, 2020
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
November 9, 2020
Press Release Signup
Subscribe to receive our Press Releases when they come out.
